
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Eterna Therapeutics Inc (ERNA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ERNA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.95% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.62M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 7.12 | 52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 |
52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2652.9% |
Management Effectiveness
Return on Assets (TTM) -32.42% | Return on Equity (TTM) -2264.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14647264 | Price to Sales(TTM) 25.45 |
Enterprise Value 14647264 | Price to Sales(TTM) 25.45 | ||
Enterprise Value to Revenue 27.38 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 7361200 | Shares Floating 1664157 |
Shares Outstanding 7361200 | Shares Floating 1664157 | ||
Percent Insiders 61.04 | Percent Institutions 1.35 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eterna Therapeutics Inc
Company Overview
History and Background
Eterna Therapeutics Inc. is a biotechnology company focusing on developing messenger RNA (mRNA) based therapies. The company leverages mRNA technology to develop novel treatments for various diseases, including cancer and genetic disorders. Specific founding year and milestones are not widely and publicly available.
Core Business Areas
- mRNA Therapeutics Development: Eterna Therapeutics develops mRNA-based drugs designed to address unmet medical needs across diverse therapeutic areas. This includes preclinical and clinical research.
- Drug Delivery Technologies: The company focuses on improving drug delivery to ensure that mRNA therapeutics reach their intended targets effectively.
- Research and Development: Eterna Therapeutics dedicates resources to researching and developing new mRNA technologies and therapeutic applications.
Leadership and Structure
Details about the specific leadership team structure are not widely accessible to the public but typical biotechnology firms have a C-suite including a CEO, CSO and CFO.
Top Products and Market Share
Key Offerings
- mRNA-Based Cancer Therapies (Preclinical): Eterna Therapeutics is developing mRNA-based cancer therapies; however, these are in the preclinical stage, so market share and revenue data are not yet available. Competitors include Moderna (MRNA), BioNTech (BNTX), and CureVac (CVAC).
- mRNA-Based Genetic Disorder Therapies (Preclinical): Similarly, Eterna Therapeutics is developing mRNA therapies for genetic disorders in the preclinical stage. Competitors include Moderna (MRNA), BioNTech (BNTX), and Sarepta Therapeutics (SRPT).
Market Dynamics
Industry Overview
The mRNA therapeutics market is experiencing rapid growth driven by the success of mRNA vaccines and the potential of mRNA technology to treat a wide range of diseases. Key trends include advancements in drug delivery systems and increasing investment in mRNA research and development.
Positioning
Eterna Therapeutics is positioned as a player in the mRNA therapeutics space, competing with larger and more established companies. Its competitive advantage would depend on proprietary technologies and novel therapeutic applications.
Total Addressable Market (TAM)
The global mRNA therapeutics market is projected to reach billions of dollars in the coming years. Eterna Therapeutics's positioning within this TAM will depend on the success of its preclinical and clinical programs. Exact TAM numbers vary depending on the source.
Upturn SWOT Analysis
Strengths
- Focus on mRNA technology
- Potential for novel therapies
- Experienced research team
- Strong intellectual property (potentially)
Weaknesses
- Early stage of development
- Limited financial resources compared to larger competitors
- Dependence on preclinical success
- Lack of approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancements in mRNA delivery technologies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established biotechnology companies
- Regulatory hurdles
- Clinical trial failures
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- CVAC
- SRPT
Competitive Landscape
Eterna Therapeutics faces significant competition from well-established mRNA companies. Success will depend on unique technologies and therapeutic breakthroughs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available.
Future Projections: Future growth projections are difficult to determine without public financial data. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives likely include advancing preclinical programs and seeking partnerships. Public details are limited.
Summary
Eterna Therapeutics is a private mRNA-focused biotechnology company in the early stages of development. Its potential lies in its focus on mRNA technologies for novel therapeutics, but it faces significant challenges from larger competitors. Securing partnerships and demonstrating preclinical success are critical for future growth and survival. Significant public data is missing given its private status.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website (limited information)
- Industry reports
- Publicly available news and press releases
Disclaimers:
Information is based on limited publicly available data and may not be entirely accurate. Market share estimates are approximate and based on the broader mRNA therapeutics market. The AI-based rating is an estimate and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eterna Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1992-10-19 | CEO, President & Director Mr. Sanjeev Luther | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.ernexatx.com |
Full time employees 6 | Website https://www.ernexatx.com |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.